文献速递临床试验与 GCP

劳拉西泮联合氟哌啶醇对比单用氟哌啶醇对接受姑息治疗的晚期癌症患者激越性谵妄的影响:一项随机临床试验

Effect of Lorazepam With Haloperidol vs Haloperidol Alone on Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2017-01-01

这项单中心双盲平行随机临床试验纳入93例晚期癌症伴激越性谵妄且已规律使用氟哌啶醇的患者,比较劳拉西泮3mg静脉注射与安慰剂作为氟哌啶醇2mg静脉注射辅助治疗的效果。结果显示,劳拉西泮组8小时RASS评分降低幅度显著大于安慰剂组(-4.1分 vs -2.3分,均差-1.9分,95%CI -2.8至-0.9,P<.001),且补救性抗精神病药用量更少、照护者与护士评估的舒适度更高。作者结论认为在此初步试验中加用劳拉西泮可更显著减少激越,但需进一步研究评估普遍性与不良反应。

要点

  • 劳拉西泮联合氟哌啶醇较单用氟哌啶醇在8小时时RASS评分降低更显著(-4.1分 vs -2.3分,P<.001)。
  • 联合组补救性抗精神病药中位用量更低(2.0mg vs 4.0mg,P=.009),照护者与护士评估舒适度更高。
  • 两组谵妄相关痛苦与生存无显著差异,最常见不良反应为运动减少。

核心结论

  • 在此初步试验中,对于晚期癌症伴激越性谵妄的住院患者,氟哌啶醇联合劳拉西泮较单用氟哌啶醇在8小时时激越减轻更显著。
  • 作者指出需进一步研究评估该结果的普遍性及不良反应。

研究设计与样本

  • 单中心、双盲、平行组随机临床试验,在德克萨斯州MD Anderson癌症中心的急性姑息治疗病房开展。
  • 2014年2月11日至2016年6月30日入组93例晚期癌症伴激越性谵妄且已规律使用氟哌啶醇的患者,数据收集于2016年10月完成。
  • 干预为在激越发作时于氟哌啶醇2mg静脉注射基础上加用劳拉西泮3mg静脉注射(n=47)或安慰剂(n=43)。

主要发现

  • 90例随机化患者(平均年龄62岁;女性42例[47%])中,58例(64%)接受了研究药物,52例(90%)完成试验。
  • 劳拉西泮联合氟哌啶醇组8小时RASS评分降低-4.1分,安慰剂联合氟哌啶醇组降低-2.3分,均差-1.9分(95%CI -2.8至-0.9;P<.001)。
  • 劳拉西泮联合氟哌啶醇组补救性抗精神病药中位用量2.0mg,低于安慰剂联合氟哌啶醇组的4.0mg,中位差-1.0mg(95%CI -2.0至0;P=.009)。
  • 盲法照护者评估舒适的比例:劳拉西泮联合氟哌啶醇组84% vs 安慰剂联合氟哌啶醇组37%,均差47%(95%CI 14%至73%,P=.007);护士评估:77% vs 30%,均差47%(95%CI 17%至71%,P=.005)。
  • 谵妄相关痛苦与生存两组间无显著差异;最常见不良反应为运动减少,劳拉西泮联合氟哌啶醇组3例(19%),安慰剂联合氟哌啶醇组4例(27%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论称此为进一步的初步试验(preliminary trial),需进一步研究评估普遍性及不良反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The use of benzodiazepines to control agitation in delirium in the last days of life is controversial. OBJECTIVE: To compare the effect of lorazepam vs placebo as an adjuvant to haloperidol for persistent agitation in patients with delirium in the setting of advanced cancer. DESIGN, SETTING, AND PARTICIPANTS: Single-center, double-blind, parallel-group, randomized clinical trial conducted at an acute palliative care unit at MD Anderson Cancer Center, Texas, enrolling 93 patients with advanced cancer and agitated delirium despite scheduled haloperidol from February 11, 2014, to June 30, 2016, with data collection completed in October 2016. INTERVENTIONS: Lorazepam (3 mg) intravenously (n = 47) or placebo (n = 43) in addition to haloperidol (2 mg) intravenously upon the onset of an agitation episode. MAIN OUTCOMES AND MEASURES: The primary outcome was change in Richmond Agitation-Sedation Scale (RASS) score (range, -5 [unarousable] to 4 [very agitated or combative]) from baseline to 8 hours after treatment administration. Secondary end points were rescue neuroleptic use, delirium recall, comfort (perceived by caregivers and nurses), communication capacity, delirium severity, adverse effects, discharge outcomes, and overall survival. RESULTS: Among 90 randomized patients (mean age, 62 years; women, 42 [47%]), 58 (64%) received the study medication and 52 (90%) completed the trial. Lorazepam + haloperidol resulted in a significantly greater reduction of RASS score at 8 hours (-4.1 points) than placebo + haloperidol (-2.3 points) (mean difference, -1.9 points [95% CI, -2.8 to -0.9]; P < .001). The lorazepam + haloperidol group required less median rescue neuroleptics (2.0 mg) than the placebo + haloperidol group (4.0 mg) (median difference, -1.0 mg [95% CI, -2.0 to 0]; P = .009) and was perceived to be more comfortable by both blinded caregivers and nurses (caregivers: 84% for the lorazepam + haloperidol group vs 37% for the placebo + haloperidol group; mean difference, 47% [95% CI, 14% to 73%], P = .007; nurses: 77% for the lorazepam + haloperidol group vs 30% for the placebo + haloperidol group; mean difference, 47% [95% CI, 17% to 71%], P = .005). No significant between-group differences were found in delirium-related distress and survival. The most common adverse effect was hypokinesia (3 patients in the lorazepam + haloperidol group [19%] and 4 patients in the placebo + haloperidol group [27%]). CONCLUSIONS AND RELEVANCE: In this preliminary trial of hospitalized patients with agitated delirium in the setting of advanced cancer, the addition of lorazepam to haloperidol compared with haloperidol alone resulted in a significantly greater reduction in agitation at 8 hours. Further research is needed to assess generalizability and adverse effects. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01949662.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Hui D, Frisbee-Hume S, Wilson A, et al. Effect of Lorazepam With Haloperidol vs Haloperidol Alone on Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical Trial. JAMA. 2017. PMID: 28975307. doi:10.1001/jama.2017.11468

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。